Martin Gisby

Martin Gisby has over 15 years of experience in healthcare, specialising in market access, drug commercialisation, and launch strategies. As an independent consultant through Magnetar Access, Martin advises clinical-stage companies on pathways to commercialisation, with a focus on neuroscience, oncology, rare diseases, and psychedelics. He co-authored a forthcoming report on psychedelics and reimbursement in Europe, blending his pharma expertise with a passion for expanding patient access.

The Psychedelic Therapies Reimbursement Challenge

As psychedelic therapies near regulatory approval in Europe, a pressing question arises: How will patients access these treatments through the NHS in the UK? This presentation examines the journey from NICE evaluation to NHS adoption, addressing unique challenges such as therapy-drug combination costs, infrastructure demands, and therapist training. Drawing on case studies and stakeholder insights, we explore practical solutions to ensure equitable access. A vital discussion for clinicians, researchers, and advocates working to integrate these transformative therapies into the UK healthcare system.